Novotech kicks off Phase Ib trials in Australia and NZ for OncoMed
Wednesday, 03 November, 2010
California-based biopharma company, OncoMed Pharmaceuticals, has announced it will run three Phase Ib clinical trials in Australia and New Zealand testing its humanised monoclonal antibody therapies for cancer.
The three separate trials, which have begun enrollment, are targeting patients pancreatic cancer, advanced colorectal cancer, and non-squamous non-small cell lung cancer (NSCLC).
OncoMed's treatments use monoclonal antibodies to target specific biologic pathways that are critical to tumour initiating cells, or so-called 'cancer stem cells'.
The trials will be run in Australia and New Zealand through the Sydney-based contract research organisation, Novotech.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
